Serum chromogranin A: Early detection of hormonal resistance in prostate cancer patients

Journal of Clinical Laboratory Analysis

Volumn 12, Issue 1, 1998, Pages 20-25

  Wu, James T ^a,b   Astill, Mark E ^a   Liu, Grace H ^a   Stephenson, Robert A ^a  

^a ARUP LABORATORIES   (United States)

^b UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

BPH; Metastases; Neuroendocrine cell; Neuroendocrine differentiation; NSE; PSA

Indexed keywords

CHROMOGRANIN A; NEURON SPECIFIC ENOLASE; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER RESISTANCE; CELL DIFFERENTIATION; CLINICAL ARTICLE; HORMONE RESISTANCE; HUMAN; MALE; METASTASIS; NEUROSECRETORY CELL; PATIENT MONITORING; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; PROSTATECTOMY;

ANDROGEN ANTAGONISTS; BIOLOGICAL MARKERS; CELL DIFFERENTIATION; CHROMOGRANIN A; CHROMOGRANINS; DRUG RESISTANCE; HUMANS; MALE; NEUROSECRETORY SYSTEMS; PHOSPHOPYRUVATE HYDRATASE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS;

EID: 0031890327     PISSN: 08878013     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2825(1998)12:1<20::AID-JCLA4>3.0.CO;2-N     Document Type: Article

References (12)

1. di Sant'Agnese PA, Cockett ATK: Neuroendocrine differentiation in prostatic malignancy. Cancer 78:357-361, 1996.
2. Tetu B, Ro JY, Ayala AF, Johnson DE, Logothetis CJ, Ordonez NG: Small cell carcinoma of the prostate: Part I. A clinicopathologic study of 20 cases. Cancer 59:1803, 1987.
3. di Sant'Agnese PA, Cockett ATK: The prostatic endocrine-paracrine (Neuroendocrine) regulatory system and neuroendocrine differentiation in prostatic carcinoma: A review and future directions in basic research. J Urol 152:1927-1937, 1994.
4. di Sant'Agnese PA: Neuroendocrine differentiation in prostatic carcinoma. Recent findings and new concepts. Cancer 75:1850-1859, 1995.
5. Cussenot O, Villette JM, Valeri A, Cariou G, Descrandschamps F, Cortesse A, Meria P, Teillac P, Fiet J, Le Duc A: Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma. J Urol 155:1340-1343, 1966.
6. Kadmon D, Thompson TC, Lynch GR, Scardino PT: Elevated plasma chromogranin-A concentrations in prostatic carcinoma. J Urol 146:358-361, 1991.
7. Angelsen A, Syversen U, Haugen OA, Stridsberg M, Kjolnerod OK, Waldum HL: Neuroendocrine differentiation in carcinomas of the prostate: Do neuroendocrine serum markers reflect immunohistochemical findings? Prostate 30:1-6, 1997.
8. Cockett ATK, Di Sant'Agnese PA, Gopinath P, Schoen S, Abrahamsson PA: Relationship on neuroendocrine cells of prostate and serotonin to benign prostatic hyperplasia. Urology 42:512, 1993.
9. Hoosein NM, Logothetis CJ, Chung LW: Differential effects of peptide hormones bombesin, vasoactive intestinal polypeptide and somatostatin analog RC-160 on the invasive capacity of human prostatic carcinoma cells. J Urol 149:1209-1213, 1993.
10. Raffo AJ, Perlman H, Chen M-W, Day ML, Streitman JS, Buttyan R: Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 55:4438-4445, 1995.
11. Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, Isola J, Trapman J, Cleutjens K, Noordzij A, Voisakorpi T, Kallioniemi O-P: Androgen receptor gene amplification: A possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 57:314-319, 1997
12. Tarle M, Rados N: Investigation on serum neuron-specific enolase in prostate cancer diagnosis and monitoring: comparative study of a multiple tumor marker assay. Prostale 19:23-27, 1991.